<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798888</url>
  </required_header>
  <id_info>
    <org_study_id>130038</org_study_id>
    <secondary_id>13-N-0038</secondary_id>
    <nct_id>NCT01798888</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation for Refractory Alcoholism</brief_title>
  <official_title>Pilot Study of Deep Brain Stimulation (DBS) for Refractory Alcoholism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Current treatments for alcoholism have limited success. More than half of people with&#xD;
      alcoholism return to uncontrolled drinking even after treatment or self-help programs. One&#xD;
      possible treatment is the use of deep brain stimulation (DBS). DBS studies of the ventral&#xD;
      capsule/ventral striatum, a region of the brain, reduced cravings for alcohol in a small&#xD;
      group of alcoholics. DBS is approved for treating other disorders, such as Parkinson s&#xD;
      disease, but not for treating alcoholism. Researchers want to study whether DBS can be used&#xD;
      to treat chronic alcoholism.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To see if deep brain stimulation is helpful and safe for people who have chronic&#xD;
      alcoholism.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Individuals between 21 and 60 years of age who have been diagnosed with chronic&#xD;
           alcoholism.&#xD;
&#xD;
        -  Participants must have tried for more than 10 years to stop drinking alcohol, and have&#xD;
           failed multiple treatment and self-help programs. They may not have any other current&#xD;
           substance abuse or dependence problem (except alcohol and nicotine).&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will start the study by entering a separate alcohol detoxification study at&#xD;
           the National Institutes of Health. They will be monitored during this study with blood&#xD;
           tests and brain scans.&#xD;
&#xD;
        -  Participants will have 2 weeks of baseline tests. They will include physical exams and&#xD;
           blood and urine tests. They will also include tests of thinking and memory, and&#xD;
           questions about current moods.&#xD;
&#xD;
        -  Participants will have surgery to insert the DBS device. Electrodes will be placed in&#xD;
           the brain and a battery pack will be placed in the chest. Participants will recover from&#xD;
           the surgery and continue the alcohol detoxification program.&#xD;
&#xD;
        -  About 4 weeks after surgery, participants will be separated into two groups. For one&#xD;
           group, the DBS device will be turned on with electrical stimulation and participants&#xD;
           will be monitored for an additional two weeks in the hospital to find the right setting&#xD;
           for the device. For the second group, participants will receive mock stimulation, but no&#xD;
           real electrical DBS, and will also be monitored for an additional two weeks in the&#xD;
           hospital.&#xD;
&#xD;
        -  Participants will return home for 24 weeks. During this time they will have frequent&#xD;
           study visits to look at the DBS device. These visits will include questions about mood&#xD;
           and memory, as well as imaging studies.&#xD;
&#xD;
        -  All participants will return for an additional two week inpatient stay in the hospital.&#xD;
           Those participant who had initially received mock stimulation will now have their&#xD;
           devices turned on with real electrical stimulation and will be monitored for the two&#xD;
           weeks to find the right setting for the device. Those participants who had initially&#xD;
           received real stimulation will continue to receive stimulation while being monitored for&#xD;
           the two weeks.&#xD;
&#xD;
        -  Participants will return home for another 24. All participants at this point will have&#xD;
           actual electrical DBS. Participants will continue to have frequent study visits for up&#xD;
           to a year to look at the DBS device. These visits will also include questions about mood&#xD;
           levels and alcohol cravings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective&#xD;
&#xD;
      The purpose of this pilot clinical study is to test the safety and efficacy of deep brain&#xD;
      stimulation (DBS) of the nucleus accumbens, ventral striatum and ventral capsule in patients&#xD;
      with treatment-resistant alcoholism and to provide critical information for planning&#xD;
      subsequent clinical trials, including additional experience with the safety of this&#xD;
      procedure.&#xD;
&#xD;
      Study Population&#xD;
&#xD;
      Ten patients 21 to 60 years of age with severe, treatment-resistant alcoholism will be&#xD;
      enrolled in this study.&#xD;
&#xD;
      Design&#xD;
&#xD;
      This study is a randomized, sham-controlled trial with open-label extension exploring the use&#xD;
      of DBS of the nucleus accumbens, ventral striatum, and ventral capsule in ten healthy alcohol&#xD;
      dependent men and women who have failed repeated alcoholism treatments.&#xD;
&#xD;
      Neurosurgical implantation of the DBS in the nucleus accumbens, ventral striatum and ventral&#xD;
      capsule will be performed. Following surgery but prior to initiation of the titration phase,&#xD;
      baseline cognitive and behavioral testing will be performed. Approximately four weeks&#xD;
      following placement of the electrodes, a randomized, sham-controlled trial with an open-label&#xD;
      extension will be instituted whereby participants will be randomized and blinded to undergo&#xD;
      either titration for two weeks followed by 24 weeks with the DBS system ON, or titration&#xD;
      followed by 24 weeks with the DBS system OFF.&#xD;
&#xD;
      After 24 weeks with DBS ON or OFF, the open-label extension phase will occur. All&#xD;
      participants will be readmitted to the hospital for the second two-week titration period. The&#xD;
      cognitive and behavioral assessments performed at baseline will be repeated. Following the&#xD;
      inpatient titration phase, they will be discharged from the hospital and followed in the&#xD;
      outpatient clinic for 24 weeks with the DBS ON. Cognitive and behavioral assessments which&#xD;
      were performed at baseline will be repeated at the end of this 24-week period. Participants&#xD;
      will be followed monthly after this time for 9 months, for a total of approximately 24 months&#xD;
      of active enrollment.&#xD;
&#xD;
      Outcome Measures&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      Safety: Risks associated with DBS for alcoholism&#xD;
&#xD;
      Efficacy: Alcohol consumption as measured by Alcohol Timeline Followback (TLFB).&#xD;
&#xD;
      Secondary Outcome Measures:&#xD;
&#xD;
      Secondary outcome measures include: 1) change in processing of rewards and punishments as&#xD;
      measured in decision-making tasks, 3) change in mood as measured by Comprehensive&#xD;
&#xD;
      Psychopathological Rating Scale (CPRS), 4) change in participation in social, physical, and&#xD;
&#xD;
      rehabilitative activities as measured by the Mayo-Portland Adaptability Inventory-4 (MPAI-4),&#xD;
      5) change in overall life satisfaction as measured by the Satisfaction with Life Scale&#xD;
      (SWLS), 6) change in alcohol craving as measured by the Penn Alcohol Craving Scale (PACS),&#xD;
      and (7) number of alcohol relapses and time to alcohol relapse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 30, 2012</start_date>
  <completion_date type="Actual">November 13, 2015</completion_date>
  <primary_completion_date type="Actual">November 13, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Test safety of DBS of the nucleus accumbens, ventral striatum and ventral capsule in patients with treatment-resistant alcoholism.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Alcoholism</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Implantation of Deep Brain Stimulation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Enrolled in 05-AA-0121.&#xD;
&#xD;
               2. Age 21-60 years at time of enrollment.&#xD;
&#xD;
               3. Fulfills DSM-IV diagnostic criteria for alcohol dependence.&#xD;
&#xD;
               4. Has no current DSM-IV substance dependence diagnoses except for alcoholism and&#xD;
                  nicotine dependence.&#xD;
&#xD;
               5. Has demonstrated greater than 10 years of refractory symptoms of alcohol&#xD;
                  dependence.&#xD;
&#xD;
               6. Has failed two or more detoxification and rehabilitation treatment programs (both&#xD;
                  inpatient and outpatient).&#xD;
&#xD;
               7. Has failed two or more community and self-help programs.&#xD;
&#xD;
               8. Has failed standard psychotherapeutic and pharmacological treatments.&#xD;
&#xD;
               9. Is unable to remain sober for more than a 6-month period (excluding periods of&#xD;
                  incarceration, inpatient treatment programs, or in a closely supervised&#xD;
                  therapeutic community) in the last 5 years.&#xD;
&#xD;
              10. Has serious psychological and/or psychosocial consequences of alcohol dependence.&#xD;
&#xD;
              11. Has a stable living arrangement (e.g., living in proximity to people who will&#xD;
                  assist with monitoring subject s behavior, encouraging subjects to attend clinic&#xD;
                  visits, and providing contact information) that will provide reasonable assurance&#xD;
                  that they will participate in follow-up evaluations following DBS implantation.&#xD;
&#xD;
              12. Is able to comprehend the consent form and provide informed consent.&#xD;
&#xD;
              13. Is fluent in the English language.&#xD;
&#xD;
          -  A physician outside of the intramural NIAAA program, who is an expert in the treatment&#xD;
             of substance abuse, will review each candidate s coded records prior to enrollment.&#xD;
             The purpose of this review is to assure that the candidate has severe, treatment&#xD;
             resistant alcoholism (as defined by criteria 5-10).&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Has medical problems requiring intensive medical or diagnostic management, including:&#xD;
&#xD;
               1. a diagnosis of acute myocardial infarction or cardiac arrest within the previous&#xD;
                  6 months&#xD;
&#xD;
               2. history of a neurosurgical ablation procedure&#xD;
&#xD;
               3. any medical contraindications to undergoing DBS surgery&#xD;
&#xD;
               4. history of hemorrhagic stroke&#xD;
&#xD;
               5. life expectancy of &lt;3 years&#xD;
&#xD;
          2. Has abnormal coagulation lab studies, defined as INR &gt;1.4, abnormal PT/PTT.&#xD;
&#xD;
          3. Has liver function tests &gt; 3 times the upper limit of normal (ULN).&#xD;
&#xD;
          4. Has infection with the Human Immunodeficiency Virus (HIV), because of the potential&#xD;
             for CNS involvement which might confound the analysis of study outcomes.&#xD;
&#xD;
          5. Is participating in other clinical trials that would compromise the ability to&#xD;
             determine the safety and efficacy of this study.&#xD;
&#xD;
          6. Has a past or present diagnosis of schizophrenia, bipolar disease, or any psychotic&#xD;
             disorder other than one determined to be substance induced; past or present diagnosis&#xD;
             of dementia or any other disorder which has led to a clinically significant cognitive&#xD;
             impairment.&#xD;
&#xD;
          7. Has manifested behaviors such as violence which, in the investigator s judgment, could&#xD;
             lead to non-compliance with study procedures.&#xD;
&#xD;
          8. Is unable to undergo MR-imaging because of implanted pacemakers, medication pumps,&#xD;
             aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or&#xD;
             cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments&#xD;
             in the eye that welders and other metal workers may have, or if candidates are&#xD;
             uncomfortable in small closed spaces (have claustrophobia), or cannot lie comfortably&#xD;
             on their back for up to one hour&#xD;
&#xD;
          9. Has known destruction and/or damage to the nucleus accumbens, ventral striatum and&#xD;
             ventral capsule region as determined by MRI.&#xD;
&#xD;
         10. Has documentation of an MRI abnormality indicative of a neurological condition that&#xD;
             may jeopardize the subject s safety, the conduct of the study, or confound the subject&#xD;
             s diagnosis or assessments.&#xD;
&#xD;
         11. Has been evaluated and judged by a board certified psychiatrist to be either severely&#xD;
             depressed or an imminent risk for suicide or violent behavior in spite of optimal&#xD;
             medical treatment.&#xD;
&#xD;
         12. Is unlikely or unable to complete the clinical trial because they are likely to be&#xD;
             incarcerated while on the protocol.&#xD;
&#xD;
         13. Is required to receive treatment by a court of law or is involuntarily committed to&#xD;
             treatment.&#xD;
&#xD;
         14. Is pregnant (negative pregnancy test required) or planning to become pregnant.&#xD;
&#xD;
         15. Has a history of seizures (including alcohol withdrawal seizures), other than&#xD;
             documented febrile seizures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kareem A Zaghloul, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Neurological Disorders and Stroke (NINDS)</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Baker KB, Kopell BH, Malone D, Horenstein C, Lowe M, Phillips MD, Rezai AR. Deep brain stimulation for obsessive-compulsive disorder: using functional magnetic resonance imaging and electrophysiological techniques: technical case report. Neurosurgery. 2007 Nov;61(5 Suppl 2):E367-8; discussion E368. doi: 10.1227/01.neu.0000303995.66902.36.</citation>
    <PMID>18091226</PMID>
  </reference>
  <reference>
    <citation>Bauer R, Pohl S, Klosterk√∂tter J, Kuhn J. [Deep brain stimulation in the context of addiction--a literature-based systematic evaluation]. Fortschr Neurol Psychiatr. 2008 Jul;76(7):396-401. doi: 10.1055/s-2008-1038217. Review. German.</citation>
    <PMID>18604773</PMID>
  </reference>
  <reference>
    <citation>Bewernick BH, Hurlemann R, Matusch A, Kayser S, Grubert C, Hadrysiewicz B, Axmacher N, Lemke M, Cooper-Mahkorn D, Cohen MX, Brockmann H, Lenartz D, Sturm V, Schlaepfer TE. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry. 2010 Jan 15;67(2):110-6. doi: 10.1016/j.biopsych.2009.09.013.</citation>
    <PMID>19914605</PMID>
  </reference>
  <verification_date>November 13, 2015</verification_date>
  <study_first_submitted>February 22, 2013</study_first_submitted>
  <study_first_submitted_qc>February 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2013</study_first_posted>
  <last_update_submitted>December 14, 2019</last_update_submitted>
  <last_update_submitted_qc>December 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep Brain Stimulation</keyword>
  <keyword>Alcohol Dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

